nodes	percent_of_prediction	percent_of_DWPC	metapath
Methylnaltrexone—CYP2D6—Parkinson's disease	0.89	1	CbGaD
Methylnaltrexone—OPRM1—telencephalic ventricle—Parkinson's disease	0.0099	0.199	CbGeAlD
Methylnaltrexone—OPRM1—nerve—Parkinson's disease	0.00624	0.126	CbGeAlD
Methylnaltrexone—OPRK1—forebrain—Parkinson's disease	0.00364	0.0732	CbGeAlD
Methylnaltrexone—OPRM1—brainstem—Parkinson's disease	0.00268	0.0539	CbGeAlD
Methylnaltrexone—OPRM1—forebrain—Parkinson's disease	0.00259	0.052	CbGeAlD
Methylnaltrexone—OPRK1—head—Parkinson's disease	0.00208	0.0419	CbGeAlD
Methylnaltrexone—OPRK1—nervous system—Parkinson's disease	0.00197	0.0397	CbGeAlD
Methylnaltrexone—OPRK1—central nervous system—Parkinson's disease	0.0019	0.0382	CbGeAlD
Methylnaltrexone—CYP2D6—hindbrain—Parkinson's disease	0.00187	0.0377	CbGeAlD
Methylnaltrexone—OPRK1—cerebellum—Parkinson's disease	0.00186	0.0374	CbGeAlD
Methylnaltrexone—OPRM1—midbrain—Parkinson's disease	0.00171	0.0344	CbGeAlD
Methylnaltrexone—OPRM1—spinal cord—Parkinson's disease	0.00167	0.0335	CbGeAlD
Methylnaltrexone—OPRK1—brain—Parkinson's disease	0.00151	0.0304	CbGeAlD
Methylnaltrexone—OPRM1—head—Parkinson's disease	0.00148	0.0298	CbGeAlD
Methylnaltrexone—OPRM1—nervous system—Parkinson's disease	0.0014	0.0283	CbGeAlD
Methylnaltrexone—OPRM1—central nervous system—Parkinson's disease	0.00135	0.0272	CbGeAlD
Methylnaltrexone—Oxymorphone—CYP2D6—Parkinson's disease	0.00108	0.17	CrCbGaD
Methylnaltrexone—CYP2D6—brainstem—Parkinson's disease	0.00107	0.0216	CbGeAlD
Methylnaltrexone—OPRM1—brain—Parkinson's disease	0.00107	0.0216	CbGeAlD
Methylnaltrexone—CYP2D6—forebrain—Parkinson's disease	0.00104	0.0209	CbGeAlD
Methylnaltrexone—Hydrocodone—CYP2D6—Parkinson's disease	0.000946	0.148	CrCbGaD
Methylnaltrexone—Oxycodone—CYP2D6—Parkinson's disease	0.000863	0.135	CrCbGaD
Methylnaltrexone—Buprenorphine—CYP2D6—Parkinson's disease	0.000795	0.125	CrCbGaD
Methylnaltrexone—Hydromorphone—CYP2D6—Parkinson's disease	0.000784	0.123	CrCbGaD
Methylnaltrexone—Naltrexone—ABCB1—Parkinson's disease	0.000773	0.121	CrCbGaD
Methylnaltrexone—CYP2D6—head—Parkinson's disease	0.000594	0.0119	CbGeAlD
Methylnaltrexone—Buprenorphine—ABCB1—Parkinson's disease	0.000568	0.0891	CrCbGaD
Methylnaltrexone—Naloxone—ABCB1—Parkinson's disease	0.000564	0.0884	CrCbGaD
Methylnaltrexone—CYP2D6—nervous system—Parkinson's disease	0.000563	0.0113	CbGeAlD
Methylnaltrexone—CYP2D6—central nervous system—Parkinson's disease	0.000542	0.0109	CbGeAlD
Methylnaltrexone—CYP2D6—cerebellum—Parkinson's disease	0.00053	0.0107	CbGeAlD
Methylnaltrexone—CYP2D6—brain—Parkinson's disease	0.00043	0.00866	CbGeAlD
Methylnaltrexone—OPRK1—GPCR ligand binding—GRM4—Parkinson's disease	0.00029	0.00535	CbGpPWpGaD
Methylnaltrexone—OPRK1—G alpha (i) signalling events—HTR1A—Parkinson's disease	0.000285	0.00525	CbGpPWpGaD
Methylnaltrexone—OPRM1—Peptide ligand-binding receptors—TAC1—Parkinson's disease	0.000281	0.00518	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2E1—Parkinson's disease	0.00028	0.00517	CbGpPWpGaD
Methylnaltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—PDYN—Parkinson's disease	0.000279	0.00514	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Oxidation by Cytochrome P450—CYP2E1—Parkinson's disease	0.000277	0.0051	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR ligand binding—PENK—Parkinson's disease	0.000275	0.00507	CbGpPWpGaD
Methylnaltrexone—OPRK1—G alpha (i) signalling events—DRD3—Parkinson's disease	0.000266	0.00491	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCRs, Class A Rhodopsin-like—HTR1A—Parkinson's disease	0.000264	0.00487	CbGpPWpGaD
Methylnaltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—ADORA2A—Parkinson's disease	0.000261	0.00481	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCRs, Class A Rhodopsin-like—ADORA2A—Parkinson's disease	0.000258	0.00475	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCRs, Class A Rhodopsin-like—DRD1—Parkinson's disease	0.000255	0.00471	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR ligand binding—PDYN—Parkinson's disease	0.000251	0.00463	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCRs, Class A Rhodopsin-like—DRD3—Parkinson's disease	0.000247	0.00456	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR ligand binding—GRM4—Parkinson's disease	0.000245	0.00452	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—DGKQ—Parkinson's disease	0.000241	0.00444	CbGpPWpGaD
Methylnaltrexone—OPRK1—G alpha (i) signalling events—DRD2—Parkinson's disease	0.000241	0.00444	CbGpPWpGaD
Methylnaltrexone—OPRM1—G alpha (i) signalling events—HTR1A—Parkinson's disease	0.000241	0.00444	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR ligand binding—GRM5—Parkinson's disease	0.000234	0.00431	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR ligand binding—PENK—Parkinson's disease	0.000232	0.00428	CbGpPWpGaD
Methylnaltrexone—OPRK1—Peptide ligand-binding receptors—EDN1—Parkinson's disease	0.000229	0.00421	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Phase 1 - Functionalization of compounds—CYP2E1—Parkinson's disease	0.000227	0.00419	CbGpPWpGaD
Methylnaltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—HTR1A—Parkinson's disease	0.000227	0.00417	CbGpPWpGaD
Methylnaltrexone—OPRM1—G alpha (i) signalling events—DRD3—Parkinson's disease	0.000225	0.00415	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCRs, Class A Rhodopsin-like—HTR7—Parkinson's disease	0.000224	0.00412	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCRs, Class A Rhodopsin-like—DRD2—Parkinson's disease	0.000224	0.00412	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCRs, Class A Rhodopsin-like—HTR1A—Parkinson's disease	0.000223	0.00412	CbGpPWpGaD
Methylnaltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—TAC1—Parkinson's disease	0.000223	0.00411	CbGpPWpGaD
Methylnaltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—ADORA2A—Parkinson's disease	0.000221	0.00407	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—GPR37—Parkinson's disease	0.000219	0.00404	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—DGKQ—Parkinson's disease	0.000219	0.00404	CbGpPWpGaD
Methylnaltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—DRD1—Parkinson's disease	0.000219	0.00403	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCRs, Class A Rhodopsin-like—DRD1—Parkinson's disease	0.000216	0.00398	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR ligand binding—PDYN—Parkinson's disease	0.000213	0.00392	CbGpPWpGaD
Methylnaltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—DRD3—Parkinson's disease	0.000212	0.0039	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCRs, Class A Rhodopsin-like—DRD3—Parkinson's disease	0.000209	0.00385	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—DGKQ—Parkinson's disease	0.000204	0.00376	CbGpPWpGaD
Methylnaltrexone—OPRM1—G alpha (i) signalling events—DRD2—Parkinson's disease	0.000204	0.00375	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—PPP1R1B—Parkinson's disease	0.0002	0.00369	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Biological oxidations—GSTA4—Parkinson's disease	0.000199	0.00367	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR ligand binding—ADORA2A—Parkinson's disease	0.000199	0.00366	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR ligand binding—GRM5—Parkinson's disease	0.000198	0.00364	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metapathway biotransformation—GSTA4—Parkinson's disease	0.000196	0.00362	CbGpPWpGaD
Methylnaltrexone—OPRM1—Peptide ligand-binding receptors—EDN1—Parkinson's disease	0.000193	0.00356	CbGpPWpGaD
Methylnaltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—DRD2—Parkinson's disease	0.000192	0.00353	CbGpPWpGaD
Methylnaltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—HTR7—Parkinson's disease	0.000192	0.00353	CbGpPWpGaD
Methylnaltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—HTR1A—Parkinson's disease	0.000191	0.00353	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCRs, Class A Rhodopsin-like—DRD2—Parkinson's disease	0.000189	0.00348	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCRs, Class A Rhodopsin-like—HTR7—Parkinson's disease	0.000189	0.00348	CbGpPWpGaD
Methylnaltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—TAC1—Parkinson's disease	0.000189	0.00347	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Phase 1 - Functionalization of compounds—MAOA—Parkinson's disease	0.000187	0.00345	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—GPR37—Parkinson's disease	0.000185	0.00341	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—DGKQ—Parkinson's disease	0.000185	0.00341	CbGpPWpGaD
Methylnaltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—DRD1—Parkinson's disease	0.000185	0.00341	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—GRK5—Parkinson's disease	0.000183	0.00337	CbGpPWpGaD
Methylnaltrexone—OPRM1—TCR Signaling Pathway—IL1B—Parkinson's disease	0.000182	0.00336	CbGpPWpGaD
Methylnaltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—DRD3—Parkinson's disease	0.000179	0.0033	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Biological oxidations—MAOB—Parkinson's disease	0.000178	0.00327	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR ligand binding—HTR1A—Parkinson's disease	0.000172	0.00318	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR ligand binding—TAC1—Parkinson's disease	0.00017	0.00313	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—PPP1R1B—Parkinson's disease	0.000169	0.00312	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR ligand binding—ADORA2A—Parkinson's disease	0.000168	0.0031	CbGpPWpGaD
Methylnaltrexone—OPRM1—TCR Signaling Pathway—MAPK8—Parkinson's disease	0.000167	0.00308	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR ligand binding—DRD1—Parkinson's disease	0.000167	0.00307	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—GRK5—Parkinson's disease	0.000166	0.00306	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—GRM4—Parkinson's disease	0.000164	0.00302	CbGpPWpGaD
Methylnaltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—HTR7—Parkinson's disease	0.000162	0.00298	CbGpPWpGaD
Methylnaltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—DRD2—Parkinson's disease	0.000162	0.00298	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR ligand binding—DRD3—Parkinson's disease	0.000161	0.00297	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCRs, Class A Rhodopsin-like—HTR2A—Parkinson's disease	0.000157	0.00289	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—VPS35—Parkinson's disease	0.000156	0.00288	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—PENK—Parkinson's disease	0.000155	0.00286	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—GRK5—Parkinson's disease	0.000154	0.00285	CbGpPWpGaD
Methylnaltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—EDN1—Parkinson's disease	0.000153	0.00283	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—GRM4—Parkinson's disease	0.000149	0.00274	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR ligand binding—HTR7—Parkinson's disease	0.000146	0.00269	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR ligand binding—DRD2—Parkinson's disease	0.000146	0.00269	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR ligand binding—HTR1A—Parkinson's disease	0.000146	0.00269	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR ligand binding—TAC1—Parkinson's disease	0.000144	0.00265	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—PDYN—Parkinson's disease	0.000142	0.00262	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—PENK—Parkinson's disease	0.000141	0.0026	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR ligand binding—DRD1—Parkinson's disease	0.000141	0.00259	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—GRK5—Parkinson's disease	0.00014	0.00258	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—GRM4—Parkinson's disease	0.000139	0.00255	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR ligand binding—DRD3—Parkinson's disease	0.000136	0.00251	CbGpPWpGaD
Methylnaltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—HTR2A—Parkinson's disease	0.000134	0.00247	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCRs, Class A Rhodopsin-like—HTR2A—Parkinson's disease	0.000132	0.00244	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—GRM5—Parkinson's disease	0.000132	0.00244	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—VPS35—Parkinson's disease	0.000132	0.00243	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—PENK—Parkinson's disease	0.000131	0.00242	CbGpPWpGaD
Methylnaltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—EDN1—Parkinson's disease	0.00013	0.00239	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—DGKQ—Parkinson's disease	0.000129	0.00238	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—GPR37—Parkinson's disease	0.000129	0.00238	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—PDYN—Parkinson's disease	0.000129	0.00238	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—GRM4—Parkinson's disease	0.000126	0.00232	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR ligand binding—DRD2—Parkinson's disease	0.000123	0.00227	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR ligand binding—HTR7—Parkinson's disease	0.000123	0.00227	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Biological oxidations—CYP2E1—Parkinson's disease	0.000121	0.00222	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—PDYN—Parkinson's disease	0.00012	0.00221	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—GRM5—Parkinson's disease	0.00012	0.00221	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—PENK—Parkinson's disease	0.000119	0.0022	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metapathway biotransformation—CYP2E1—Parkinson's disease	0.000119	0.00219	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PPP1R1B—Parkinson's disease	0.000118	0.00218	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR ligand binding—EDN1—Parkinson's disease	0.000117	0.00215	CbGpPWpGaD
Methylnaltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—HTR2A—Parkinson's disease	0.000113	0.00209	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—ADORA2A—Parkinson's disease	0.000112	0.00207	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—GRM5—Parkinson's disease	0.000112	0.00206	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—GPR37—Parkinson's disease	0.000109	0.00201	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—DGKQ—Parkinson's disease	0.000109	0.00201	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—PDYN—Parkinson's disease	0.000109	0.00201	CbGpPWpGaD
Methylnaltrexone—OPRM1—TCR Signaling Pathway—IL6—Parkinson's disease	0.000107	0.00197	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—RIT2—Parkinson's disease	0.000103	0.00191	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR ligand binding—HTR2A—Parkinson's disease	0.000102	0.00188	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—ADORA2A—Parkinson's disease	0.000102	0.00188	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—GRM5—Parkinson's disease	0.000101	0.00187	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Biological oxidations—COMT—Parkinson's disease	0.0001	0.00184	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PPP1R1B—Parkinson's disease	0.0001	0.00184	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Biological oxidations—GSTP1—Parkinson's disease	9.95e-05	0.00183	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Biological oxidations—MAOA—Parkinson's disease	9.93e-05	0.00183	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR ligand binding—EDN1—Parkinson's disease	9.87e-05	0.00182	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metapathway biotransformation—COMT—Parkinson's disease	9.86e-05	0.00182	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metapathway biotransformation—GSTP1—Parkinson's disease	9.82e-05	0.00181	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—GRK5—Parkinson's disease	9.8e-05	0.00181	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—HTR1A—Parkinson's disease	9.75e-05	0.0018	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—TAC1—Parkinson's disease	9.6e-05	0.00177	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—ADORA2A—Parkinson's disease	9.5e-05	0.00175	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—DRD1—Parkinson's disease	9.41e-05	0.00174	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Biological oxidations—GSTM1—Parkinson's disease	9.15e-05	0.00169	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—DRD3—Parkinson's disease	9.12e-05	0.00168	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metapathway biotransformation—GSTM1—Parkinson's disease	9.02e-05	0.00166	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—HTR1A—Parkinson's disease	8.85e-05	0.00163	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—GRM4—Parkinson's disease	8.79e-05	0.00162	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—RIT2—Parkinson's disease	8.74e-05	0.00161	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—TAC1—Parkinson's disease	8.72e-05	0.00161	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR ligand binding—HTR2A—Parkinson's disease	8.64e-05	0.00159	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—ADORA2A—Parkinson's disease	8.62e-05	0.00159	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—DRD1—Parkinson's disease	8.55e-05	0.00158	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—ADRBK1—Parkinson's disease	8.51e-05	0.00157	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PENK—Parkinson's disease	8.34e-05	0.00154	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—MAG—Parkinson's disease	8.34e-05	0.00154	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—GRK5—Parkinson's disease	8.29e-05	0.00153	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—DRD3—Parkinson's disease	8.28e-05	0.00153	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—HTR7—Parkinson's disease	8.25e-05	0.00152	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—DRD2—Parkinson's disease	8.25e-05	0.00152	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—HTR1A—Parkinson's disease	8.24e-05	0.00152	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—TAC1—Parkinson's disease	8.11e-05	0.0015	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—DRD1—Parkinson's disease	7.96e-05	0.00147	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—ADRBK1—Parkinson's disease	7.73e-05	0.00142	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—DRD3—Parkinson's disease	7.71e-05	0.00142	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PDYN—Parkinson's disease	7.62e-05	0.00141	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—DRD2—Parkinson's disease	7.49e-05	0.00138	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—HTR7—Parkinson's disease	7.49e-05	0.00138	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—HTR1A—Parkinson's disease	7.48e-05	0.00138	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—GRM4—Parkinson's disease	7.43e-05	0.00137	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—TAC1—Parkinson's disease	7.37e-05	0.00136	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—DRD1—Parkinson's disease	7.23e-05	0.00133	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—ADRBK1—Parkinson's disease	7.2e-05	0.00133	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—GFAP—Parkinson's disease	7.17e-05	0.00132	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—GRM5—Parkinson's disease	7.09e-05	0.00131	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PENK—Parkinson's disease	7.05e-05	0.0013	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—MAG—Parkinson's disease	7.05e-05	0.0013	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—DRD3—Parkinson's disease	7e-05	0.00129	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—HTR7—Parkinson's disease	6.97e-05	0.00128	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—DRD2—Parkinson's disease	6.97e-05	0.00128	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—EDN1—Parkinson's disease	6.6e-05	0.00122	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—ADRBK1—Parkinson's disease	6.53e-05	0.0012	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—ND3—Parkinson's disease	6.49e-05	0.0012	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—MCCC1—Parkinson's disease	6.49e-05	0.0012	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PDYN—Parkinson's disease	6.44e-05	0.00119	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—DRD2—Parkinson's disease	6.33e-05	0.00117	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—HTR7—Parkinson's disease	6.33e-05	0.00117	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—FGF20—Parkinson's disease	6.22e-05	0.00115	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—TALDO1—Parkinson's disease	6.1e-05	0.00112	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—OMD—Parkinson's disease	6.1e-05	0.00112	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—GFAP—Parkinson's disease	6.06e-05	0.00112	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—ADORA2A—Parkinson's disease	6.03e-05	0.00111	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—EDN1—Parkinson's disease	6e-05	0.0011	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—GRM5—Parkinson's disease	5.99e-05	0.0011	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—NDUFB11—Parkinson's disease	5.78e-05	0.00107	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—HTR2A—Parkinson's disease	5.78e-05	0.00106	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—EDN1—Parkinson's disease	5.58e-05	0.00103	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—INSR—Parkinson's disease	5.56e-05	0.00103	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—GCH1—Parkinson's disease	5.51e-05	0.00102	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—FGB—Parkinson's disease	5.26e-05	0.000969	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—FGF20—Parkinson's disease	5.25e-05	0.000968	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—HTR2A—Parkinson's disease	5.24e-05	0.000967	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—HTR1A—Parkinson's disease	5.23e-05	0.000964	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—TAC1—Parkinson's disease	5.15e-05	0.000949	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—ADORA2A—Parkinson's disease	5.09e-05	0.000939	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—EDN1—Parkinson's disease	5.07e-05	0.000934	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—DRD1—Parkinson's disease	5.05e-05	0.000931	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—DBH—Parkinson's disease	4.91e-05	0.000906	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—FBP1—Parkinson's disease	4.91e-05	0.000906	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—GBA—Parkinson's disease	4.91e-05	0.000906	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—DRD3—Parkinson's disease	4.89e-05	0.000901	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—HTR2A—Parkinson's disease	4.88e-05	0.0009	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—INSR—Parkinson's disease	4.7e-05	0.000866	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—ADRBK1—Parkinson's disease	4.57e-05	0.000842	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—FGB—Parkinson's disease	4.44e-05	0.000819	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—HTR2A—Parkinson's disease	4.43e-05	0.000817	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—HTR7—Parkinson's disease	4.42e-05	0.000815	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—DRD2—Parkinson's disease	4.42e-05	0.000815	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—HTR1A—Parkinson's disease	4.42e-05	0.000814	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—TAC1—Parkinson's disease	4.35e-05	0.000802	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—DRD1—Parkinson's disease	4.27e-05	0.000787	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—DRD3—Parkinson's disease	4.13e-05	0.000762	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—ADRBK1—Parkinson's disease	3.86e-05	0.000711	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—DRD2—Parkinson's disease	3.74e-05	0.000689	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—HTR7—Parkinson's disease	3.74e-05	0.000689	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—IGF2—Parkinson's disease	3.71e-05	0.000683	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—DDC—Parkinson's disease	3.61e-05	0.000665	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—IGF1R—Parkinson's disease	3.58e-05	0.000661	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—EDN1—Parkinson's disease	3.54e-05	0.000653	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—GSTA4—Parkinson's disease	3.41e-05	0.000628	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—NGF—Parkinson's disease	3.25e-05	0.0006	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—IGF2—Parkinson's disease	3.13e-05	0.000577	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—HTR2A—Parkinson's disease	3.1e-05	0.000571	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PLA2G6—Parkinson's disease	3.07e-05	0.000565	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—MAOB—Parkinson's disease	3.04e-05	0.00056	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—IGF1R—Parkinson's disease	3.03e-05	0.000558	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—EDN1—Parkinson's disease	2.99e-05	0.000552	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—APOE—Parkinson's disease	2.88e-05	0.000531	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—NGF—Parkinson's disease	2.75e-05	0.000507	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—HTR2A—Parkinson's disease	2.62e-05	0.000483	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—INS—Parkinson's disease	2.46e-05	0.000453	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—APOE—Parkinson's disease	2.43e-05	0.000449	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—CTGF—Parkinson's disease	2.22e-05	0.000408	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—INS—Parkinson's disease	2.08e-05	0.000383	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—CYP2E1—Parkinson's disease	2.06e-05	0.00038	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—NQO1—Parkinson's disease	2.04e-05	0.000376	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—TH—Parkinson's disease	2.01e-05	0.000371	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—CYCS—Parkinson's disease	1.93e-05	0.000356	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CASP3—Parkinson's disease	1.83e-05	0.000338	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—IL6—Parkinson's disease	1.82e-05	0.000335	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—COMT—Parkinson's disease	1.71e-05	0.000315	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—GSTP1—Parkinson's disease	1.7e-05	0.000314	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—MAOA—Parkinson's disease	1.7e-05	0.000313	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—MAPK8—Parkinson's disease	1.68e-05	0.00031	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—HMOX1—Parkinson's disease	1.68e-05	0.000309	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—ABCB1—Parkinson's disease	1.61e-05	0.000297	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—GSTM1—Parkinson's disease	1.56e-05	0.000288	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CASP3—Parkinson's disease	1.55e-05	0.000285	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—IL6—Parkinson's disease	1.54e-05	0.000283	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—GPX1—Parkinson's disease	1.5e-05	0.000276	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—MAPK8—Parkinson's disease	1.42e-05	0.000262	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—MTHFR—Parkinson's disease	1.38e-05	0.000255	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—APOE—Parkinson's disease	1.29e-05	0.000237	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—INS—Parkinson's disease	1.1e-05	0.000203	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—IL6—Parkinson's disease	1.08e-05	0.000198	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—IL6—Parkinson's disease	9.09e-06	0.000167	CbGpPWpGaD
